Page 35 - GALENIKA MEDICAL JOURNAL

6. Coutinho AE, Chapman KE. The anti-inflammatory and 23. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga
immunosuppressive effects of glucocorticoids, recent developments VC, et al; COALITION COVID-19 Brazil III Investigators. Effect of
and mechanistic insights. Mol Cell Endocrinol. 2011 Mar 15;335(1):2-13. Dexamethasone on Days Alive and Ventilator-Free in Patients With
Moderate or Severe Acute Respiratory Distress Syndrome and
7. Udovicic I, Stanojevic I, Djordjevic D, Zeba S, Rondovic G, Abazovic T, COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020 Oct
et al. Immunomonitoring of Monocyte and Neutrophil Function in 6;324(13):1307-16.
Critically Ill Patients: From Sepsis and/or Trauma to COVID-19. J Clin
Med. 2021 Dec 12;10(24):5815. 24. RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, Mafham
M, Bell JL, Linsell L, et al. Dexamethasone in Hospitalized Patients with
8. Pfortmueller CA, Meisel C, Fux M, Schefold JC. Assessment of immune Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704.
organ dysfunction in critical illness: utility of innate immune response
markers. Intensive Care Med Exp. 2017 Oct 23;5(1):49. 25. REMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, Rowan
KM, Nichol AD, Arabi YM, et al. Interleukin-6 Receptor Antagonists
9. Ferrer M, Travierso C, Cilloniz C, Gabarrus A, Ranzani OT, Polverino in Critically Ill Patients with Covid-19. N Engl J Med. 2021 Apr
E, et al. Severe community-acquired pneumonia: Characteristics and 22;384(16):1491-502.
prognostic factors in ventilated and non-ventilated patients. PLoS One.
2018 Jan 25;13(1):e0191721. 26. RECOVERY Collaborative Group. Tocilizumab in patients admitted to
hospital with COVID-19 (RECOVERY): a randomised, controlled, open-
10. Corrales-Medina VF, Musher DM. Immunomodulatory agents in the label, platform trial. Lancet. 2021 May 1;397(10285):1637-45.
treatment of community-acquired pneumonia: a systematic review. J
Infect. 2011 Sep;63(3):187-99. 27. Butler E, Munch MW, Venkatesh B. Time for tocilizumab in COVID-19?
Intensive Care Med. 2021 Jun;47(6):692-4.
11. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K,
et al. Diagnosis and Treatment of Adults with Community-acquired 28. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT)
Pneumonia. An Official Clinical Practice Guideline of the American Working Group; Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D,
Thoracic Society and Infectious Diseases Society of America. Am J Respir Higgins JPT, Spiga F, et al. Association Between Administration of IL-6
Crit Care Med. 2019 Oct 1;200(7):e45-e67. Antagonists and Mortality Among Patients Hospitalized for COVID-19: A
Meta-analysis. JAMA. 2021 Aug 10;326(6):499-518.
12. Pastores SM, Annane D, Rochwerg B; Corticosteroid Guideline
Task Force of SCCM and ESICM. Guidelines for the diagnosis and 29. Matthay MA, Luetkemeyer AF. IL-6 Receptor Antagonist Therapy for
management of critical illness-related corticosteroid insufficiency Patients Hospitalized for COVID-19: Who, When, and How? JAMA. 2021
(CIRCI) in critically ill patients (Part II): Society of Critical Care Medicine Aug 10;326(6):483-5.
(SCCM) and European Society of Intensive Care Medicine (ESICM) 2017.
Intensive Care Med. 2018 Apr;44(4):474-7. 30. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French
C, et al. Surviving Sepsis Campaign: International Guidelines for
13. Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, et al. Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021 Nov
Effect of corticosteroids on treatment failure among hospitalized 1;49(11):e1063-e1143.
patients with severe community-acquired pneumonia and high
inflammatory response: a randomized clinical trial. JAMA. 2015 Feb 31. Bentzer P, Fjell C, Walley KR, Boyd J, Russell JA. Plasma cytokine levels
17;313(7):677-86. predict response to corticosteroids in septic shock. Intensive Care Med.
2016 Dec;42(12):1970-9.
14. Ye Z, Wang Y, Colunga-Lozano LE, Prasad M, Tangamornsuksan W,
Rochwerg B, et al. Efficacy and safety of corticosteroids in COVID-19 32. König R, Kolte A, Ahlers O, Oswald M, Krauss V, Roell D, et al. Use of
based on evidence for COVID-19, other coronavirus infections, IFNγ/IL10 Ratio for Stratification of Hydrocortisone Therapy in Patients
influenza, community-acquired pneumonia and acute respiratory With Septic Shock. Front Immunol. 2021 Mar 9;12:607217.
distress syndrome: a systematic review and meta-analysis. CMAJ. 2020 33. Jung C, Wernly B, Fjølner J, Bruno RR, Dudzinski D, Artigas A, et al; and
Jul 6;192(27):E756-E767. the COVIP study group. Steroid use in elderly critically ill COVID-19
15. Saleem N, Kulkarni A, Snow TAC, Ambler G, Singer M, Arulkumaran N. patients. Eur Respir J. 2021 Oct 7;58(4):2100979.
Effect of Corticosteroids on Mortality and Clinical Cure in Community- 34. Grasselli G, Scaravilli V, Mangioni D, Scudeller L, Alagna L, Bartoletti
Acquired Pneumonia: A Systematic Review, Meta-analysis, and Meta- M, et al. Hospital-Acquired Infections in Critically Ill Patients With
regression of Randomized Control Trials. Chest. 2023 Mar;163(3):484- COVID-19. Chest. 2021 Aug;160(2):454-65.
97.
35. Gragueb-Chatti I, Lopez A, Hamidi D, Guervilly C, Loundou A, Daviet F, et
16. Huang J, Guo J, Li H, Huang W, Zhang T. Efficacy and safety of adjunctive al. Impact of dexamethasone on the incidence of ventilator-associated
corticosteroids therapy for patients with severe community-acquired pneumonia and blood stream infections in COVID-19 patients requiring
pneumonia: A systematic review and meta-analysis. Medicine invasive mechanical ventilation: a multicenter retrospective study. Ann
(Baltimore). 2019 Mar;98(13):e14636. Intensive Care. 2021 May 31;11(1):87.
17. Dequin PF, Meziani F, Quenot JP, Kamel T, Ricard JD, Badie J, et al. CRICS- 36. Scaravilli V, Guzzardella A, Madotto F, Beltrama V, Muscatello A, Bellani
TriGGERSep Network. Hydrocortisone in Severe Community-Acquired G, et al. Impact of dexamethasone on the incidence of ventilator-
Pneumonia. N Engl J Med. 2023 May 25;388(21):1931-41. associated pneumonia in mechanically ventilated COVID-19 patients: a
18. Urwyler SA, Blum CA, Coslovsky M, Mueller B, Schuetz P, Christ-Crain propensity-matched cohort study. Crit Care. 2022 Jun 13;26(1):176.
M. Cytokines and Cortisol - predictors of treatment response to 37. Sinha P, Furfaro D, Cummings MJ, Abrams D, Delucchi K, Maddali MV,
corticosteroids in community-acquired pneumonia? J Intern Med. 2019 et al. Latent Class Analysis Reveals COVID-19-related Acute Respiratory
Jul;286(1):75-87. Distress Syndrome Subgroups with Differential Responses to
19. Villar J, Ferrando C, Martínez D, Ambrós A, Muñoz T, Soler JA, et al; Corticosteroids. Am J Respir Crit Care Med. 2021 Dec 1;204(11):1274-85.
dexamethasone in ARDS network. Dexamethasone treatment for
the acute respiratory distress syndrome: a multicentre, randomised
controlled trial. Lancet Respir Med. 2020 Mar;8(3):267-76.
Konflikt interesa: Nema
20. Chaudhuri D, Sasaki K, Karkar A, Sharif S, Lewis K, Mammen MJ, et al.
Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic Primljeno: 15. 05. 2023.
review and meta-analysis. Intensive Care Med. 2021 May;47(5):521-37.
Prihvaćeno: 09. 06. 2023.
21. Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al. Effect Onlajn: 01. 09. 2023.
of Hydrocortisone on Mortality and Organ Support in Patients With
Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain
Randomized Clinical Trial. JAMA. 2020 Oct 6;324(13):1317-29.
22. Dequin PF, Heming N, Meziani F, Plantefève G, Voiriot G, Badié J, et al;
CAPE COVID Trial Group and the CRICS-TriGGERSep Network. Effect of
Hydrocortisone on 21-Day Mortality or Respiratory Support Among
Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA.
2020 Oct 6;324(13):1298-306.

REVIJALNI RADOVI Galenika Medical Journal, 2023; 2(7):27-33. 33